Needlescopic versus transvaginal/transumbilical cholecystectomy: a randomized clinical trial

Organizational Data

DRKS-ID:
DRKS00000341
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2010-02-24
Last update in DRKS:
2017-08-11
Registration type:
Retrospective

Acronym/abbreviation of the study

NATCH

URL of the study

No Entry

Brief summary in lay language

Laparoscopic surgery has become the golden standard for the removal of the gallbladder. Recently, developments have been made so that operations can be performed through a natural orifice instead of the abdominal wall, thus minimizing the trauma of a procedure. This study compares the transvaginal/transumbilical cholecystectomy with the laparoscopic operation using 2-3mm instruments in female patients. It also examines the benefits and disadvantages related to postoperative pain, cosmetic aspects, and potential physiological alterations to the transvaginal approach that affect sexual intercourse.

Brief summary in scientific language

The amount of trauma inflicted, especially in abdominal operations, depends largely on target organ access. Great efforts have been made to minimize access trauma. The further development of laparoscopy led to the miniaturization of surgical instruments and otherwise the use of natural orifices, like the stomach, rectum or vagina. The cholecystectomy is currently performed needlescopicly with 2-3 mm trocars and in transumbilically assisted transvaginal technique. The aim of this randomized study is to compare these two techniques in female patients that are in need of an elective cholecystectomy. The patients will be randomized on a 1:1 ratio into two treatment groups. In the needlescopic group we will use two 2-3 mm working trocars and one 10 mm optic trocar, also to extract the gallbladder. In the transvaginal/transumbilical group we will perform the Zornig technique using a 5 mm trocar in the umbilicus and a 10 mm trocar together with a 5 mm seizing forceps through the posterior vaginal vault. The primary endpoint of this trial is to measure the intensity of pain in motion measured from the day of the operation until postoperative day 2. Four different measurements of pain will be used. Furthermore we examine perioperative complications as security parameters. The trial is supported in part by the German Ministry of Research and Education (CHIR-Net grant, BMBF No. 01-GH-0605).

Health condition or problem studied

ICD10:
K80.20
ICD10:
K80.10
Free text:
5-511.11: Laparoscopic cholecystectomy
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
Needlescopic cholecystectomy with 3 trocars: we will use two 2-3 mm working trocars and one 10 mm optic trocar, its access is also used for extraction of the gallbladder.
Arm 2:
Transvaginal/transumbilical group: we will use a 5 mm trocar in the umbilicus and a 10 mm trocar together with a 5 mm seizing forceps through the posterior vaginal vault to perform the cholecystectomy in the Zornig style.

Endpoints

Primary outcome:
Intensity of pain in motion measured from operation day to postoperative day 2. This outcome includes a total of 4 measurements.
Secondary outcome:
Cosmetic aspects and overall satisfaction with the results of the surgery: 1 (complete satisfaction) to 5 (complete dissatisfaction) scale. || Intraoperative complications, undesirable events, conversions. || Duration of the operation (in minutes). || Surgical handling for the first and second surgeon on a 1 to 5 scale. || Intensity of pain in motion measured from postoperative day 2 to 10. This outcome includes a total of 17 measurements. || Use of analgesics: quantity, dose and class of the used drugs between the operative day and postoperative day 10. || Postoperative complications including frequency of reoperation. || Return to everyday, work related and free time activities: duration of limitations. || Quality of life measured on postoperative day 10 with the Gastrointestinal Quality of Life Index (GIQLI) from Eypasch et al. || Postoperative restrictions of sexual function: to be measured 3 months after surgery with part of the "female sexual function index" (FSFI-D). || Morphological consequences of transvaginal access: all patients from the transvaginal/transumbilical group will be examined by a gynaecologist before their operation, and again 10 to 14 days and 6 months after their surgery.

Study Design

Purpose:
Treatment
Allocation:
Randomized controlled study
Control:
  • Active control (effective treatment of control group)
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
No Entry

Recruitment period and number of participants

Planned study start date:
No Entry
Actual study start date:
2010-02-19
Planned study completion date:
No Entry
Actual Study Completion Date:
2013-01-04
Target Sample Size:
40
Final Sample Size:
40

Inclusion Criteria

Sex:
Female
Minimum Age:
18 Years
Maximum Age:
80 Years
Additional Inclusion Criteria:
Female gender; indication for elective cholecystectomy on account of symptomatic cholecystolithiasis; age >=18 years and <=80 years; legal competence.

Exclusion Criteria

Acute cholecystitis or locally complicated disease (gallbladder empyema, choledocholithisis, pancreatitis, etc.); liver cirrhosis (Child Pugh A, B, C); severe comorbidity, class IV or V as defined by the American Society for Anesthesiologists (ASA); intact hymen; acute vaginal infection; lacking visibility of the uterine orifice; endometriosis; malignoma; obesity with a Body Mass Index (BMI) > 40 kg/m2; chronic abuse of analagesics or alcohol; neuromuscular disease that could interfere treatment or measures of pain; history of major abdominal surgery with a high risk of intraperitoneal adhesions (minor operations such as an appendectomy, inguinal hernia repair, minor gynaecological surgery, etc. will not be considered exclusion criteria); gravidity or breastfeeding; allergy against analgesics; patients who are dependent on or employed by the trial sponsor or physicians; institutionalisation for legal reasons; participation in other clinical studies that could interfere with the present trial; no written informed consent signed.

Addresses

Primary Sponsor

Address:
Klinik für Viszeral-, Gefäß- und Transplantationschirurgie Lehrstuhl Chirurgie I Universitätsklinikum Witten/Herdecke mit Sitz in Köln Krankenhaus Merheim
Ostmerheimerstr. 200
51109 Köln
Germany
Telephone:
0221-8907-3770
Fax:
0221-8907-8561
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.kliniken-koeln.de/krankenhaeuser/KrankenhausMerheim/Viszeralchirurgie/
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Dr. med. Stefan Sauerland
Dillenburger Straße 27
51105 Köln
Germany
Telephone:
+49 (0)221 / 356 85 - 359
Fax:
+49 (0)221 / 356 85 - 873
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.iqwig.de

Contact for Public Queries

Address:
Klinik für Viszeral-, Gefäß- und Transplantationschirurgie Lehrstuhl Chirurgie I Universitätsklinikum Witten/Herdecke mit Sitz in Köln Krankenhaus Merheim
Dr. med. Dirk R. Bulian
Ostmerheimerstr. 200
51109 Köln
Germany
Telephone:
0221-8907-3770
Fax:
0221-8907-8561
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.kliniken-koeln.de/krankenhaeuser/KrankenhausMerheim/Viszeralchirurgie/

Sources of Monetary or Material Support

Institutional budget, no external funding (budget of sponsor/PI)

Address:
Klinik für Viszeral-, Gefäß- und Transplantationschirurgie Lehrstuhl Chirurgie I Universitätsklinikum Witten/Herdecke mit Sitz in Köln Krankenhaus Merheim
Ostmerheimerstr. 200
51109 Köln
Germany
Telephone:
0221-8907-3770
Fax:
0221-8907-8561
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.kliniken-koeln.de/krankenhaeuser/KrankenhausMerheim/Viszeralchirurgie/

Ethics Committee

Address Ethics Committee

Address:
Ethik-Kommission der Universität Witten/Herdecke
Alfred-Herrhausen-Str. 50
58448 Witten
Germany
Telephone:
+49-2302-926740
Fax:
+49-2302-926739
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2009-11-17
Ethics committee number:
89/2009
Vote of the Ethics Committee:
Approved
Date of the vote:
2010-01-25

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
U1111-1114-7386
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No Entry
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
Transvaginal/Transumbilical Hybrid—NOTES—Versus 3-Trocar Needlescopic Cholecystectomy: Short-Term Results of a Randomized Clinical Trial
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry